Goran Rikner

Title: Goran Rikner: Innovator in Detector Response Modeling

Introduction

Goran Rikner is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of radiotherapy through his innovative work in detector response modeling. His expertise lies in developing methods that enhance the accuracy of dosimetry in modern radiation therapy.

Latest Patents

Goran Rikner holds a patent for a "Detector response correction arrangement and method." This invention proposes a system for the online determination of correction factors for arbitrary positions from arbitrary incident fluence distributions. As modern radiotherapy utilizes more of the available degrees of freedom of radiation machines, reliable dosimetry measurements are essential. The patent employs the Monte Carlo technique to precalculate fluence pencil kernels from a monodirectional beam, allowing for a comprehensive description of particle fluence in an irradiated medium. The method assumes that the particle fluence remains largely unchanged by the introduction of a small detector volume, enabling the integration of fluence pencil kernels and the determination of correction factors using Cavity Theory.

Career Highlights

Goran Rikner is associated with IBA S.A., a company known for its advancements in radiation therapy technology. His work has been pivotal in improving the precision of radiation dose delivery, which is crucial for effective cancer treatment. With a focus on innovation, Rikner continues to contribute to the field through his research and development efforts.

Collaborations

Goran has collaborated with esteemed colleagues such as Anders Ahnesjö and Karin Eklund. Their combined expertise has furthered advancements in the field of radiotherapy and dosimetry.

Conclusion

Goran Rikner's contributions to detector response modeling represent a significant advancement in the field of radiotherapy. His innovative patent and collaborative efforts continue to enhance the accuracy and reliability of radiation dose measurements, ultimately benefiting patient care in cancer treatment.